Tissue factor (TF) pathway inhibitor (TFPI) is an anticoagulant protein that inhibits early
phases of the procoagulant response. Alternatively spliced isoforms of TFPI are differentially …

Hemophilia is a severe bleeding disorder treated by infusion of the missing blood
coagulation protein, factor VIII or factor IX. The discovery and characterization of the …

Many subjects carrying inherited thrombophilic defects will never experience venous
thromboembolism (VTE) while other individuals developed recurrent VTE with no known …

Tissue factor pathway inhibitor (TFPI) down-regulates the extrinsic coagulation pathway by
inhibiting FXa and FVIIa. Both TFPI and FXa interact with several plasma proteins (eg …

Background Growth arrest-specific gene 6 (Gas6), a vitamin K-dependent protein interacting
with anionic phospholipids and TAM tyrosine kinase receptors, is elevated in plasma of …

Deficiency of antithrombin (AT), protein C (PC) or protein S (PS) constitutes a major risk
factor for venous thromboembolism (VTE). Individuals at high risk for recurrence who benefit …

Large vessel arterial disease may be regarded as atherosclerotic or nonatherosclerotic; the
latter includes less common diseases related to known genetic abnormalities, degenerative …

Protein S (PS), a γ-carboxyglutamate-containing serum protein, was unexpectedly
discovered in 1977. Soon after its discovery, PS gained the attention of researchers because …

Warfarin is the anticoagulant of choice for venous thromboembolism (VTE) treatment,
although its suppression of the endogenous clot‐dissolution complex APC: PS may …

Venous thrombosis is a typical common complex disease as acquired and genetic causes
play a role in its development. The different „loss of function “mutations of the natural …